Quest Commences Offer for Celera | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today said that it has commenced its tender offer to acquire Celera for $8 per share.

The offer is being made through Quest's wholly owned subsidiary, Spark Acquisition Corp., and will expire on April 25 at 5:00 pm New York City time. The offer is subject to customary conditions, including the tender of a majority of Celera's outstanding shares and certain regulatory approvals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.